Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Life Sci ; 84(15-16): 537-43, 2009 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-19232362

RESUMEN

AIMS: Adhesion formation following abdominal intervention is an abnormal peritoneal healing process. Our aim was to investigate the effects of controlling adhesion development by inhibiting its key components (angiogenesis, inflammation and fibrosis) using phosphodiesterase (PDE) inhibitors. MAIN METHODS: Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion. Angiogenesis was assessed by hemoglobin content, vascular endothelial growth factor (VEGF) levels, and morphometric analysis. Accumulation of neutrophils and macrophages was determined by measuring myeloperoxidase (MPO) and N-acetylglucosaminidase (NAG) activities, respectively. Levels of TNF-alpha were also determined. Fibrosis was assessed by determining the amount of collagen in the implant; TGF-beta1 levels in the implant were also measured. KEY FINDINGS: Our results show that the treatments attenuated the main components of the adhesion tissue by reducing the amount of fibrovascular tissue that infiltrated the sponge matrix (wet weight). Hemoglobin content and VEGF levels were also decreased by approximately 40%. Neutrophil accumulation was unaffected by the compounds. However, NAG activity was reduced by pentoxifylline, but not by cilostazol. These compounds also decreased the levels of the pro-inflammatory and pro-fibrogenic cytokines TNF-alpha and TGF-beta1, respectively, and collagen synthesis. SIGNIFICANCE: Our results suggest that cilostazol and PTX decreased the development of peritoneal adhesions in the model, which might be associated with cyclic nucleotide modulation. Therapies to intervene in these pathways may be beneficial for the prevention of these lesions.


Asunto(s)
Inflamación/prevención & control , Neovascularización Patológica/prevención & control , Pentoxifilina/uso terapéutico , Peritoneo/efectos de los fármacos , Inhibidores de Fosfodiesterasa/uso terapéutico , Tetrazoles/uso terapéutico , Adherencias Tisulares/tratamiento farmacológico , Animales , Cilostazol , Modelos Animales de Enfermedad , Fibrosis/enzimología , Fibrosis/inmunología , Fibrosis/patología , Fibrosis/prevención & control , Inflamación/enzimología , Inflamación/inmunología , Inflamación/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Neovascularización Patológica/enzimología , Neovascularización Patológica/inmunología , Neovascularización Patológica/patología , Pentoxifilina/administración & dosificación , Peritoneo/irrigación sanguínea , Peritoneo/enzimología , Peritoneo/inmunología , Peritoneo/patología , Inhibidores de Fosfodiesterasa/administración & dosificación , Tapones Quirúrgicos de Gaza , Tetrazoles/administración & dosificación , Adherencias Tisulares/enzimología , Adherencias Tisulares/etiología , Adherencias Tisulares/inmunología , Adherencias Tisulares/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA